Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.47 extracted from

  • Ruggenenti, P.; Daina, E.; Gennarini, A.; Carrara, C.; Gamba, S.; Noris, M.; Rubis, N.; Peraro, F.; Gaspari, F.; Pasini, A.; Rigotti, A.; Lerchner, R.M.; Santoro, D.; Pisani, A.; Pasi, A.; Remuzzi, G.; Remuzzi, G.
    C5 convertase blockade in membranoproliferative glomerulonephritis a single-arm clinical trial (2019), Am. J. Kidney Dis., 74, 224-238 .
    View publication on PubMed
Search for more literature for 3.4.21.47

Inhibitors

Inhibitors Comment Organism Structure
eculizumab
-
 Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
complement component C5 + H2O Homo sapiens
-
 complement component C5a + complement component C5b
-
 ?

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
complement component C5 + H2O
-
 Homo sapiens complement component C5a + complement component C5b
-
 ?

Synonyms

Synonyms Comment Organism
C5 convertase
-
 Homo sapiens

General Information

General Information Comment Organism
malfunction enzyme inhibition with eculizumab blunts terminal complementxa0activation in patients with immunexa0complex-mediated primary membranoproliferative glomerulonephritis or C3 glomerulonephritis and nephrotic syndrome Homo sapiens